Technical Analysis for OCUL - Ocular Therapeutix, Inc.

Grade Last Price % Change Price Change
grade F 3.37 -2.60% -0.09
OCUL closed down 2.6 percent on Monday, May 20, 2019, on 1.24 times normal volume. The bears made the stock sink to a new 52-week low. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical OCUL trend table...

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
Lower Bollinger Band Walk Weakness 0.00%
New 52 Week Low Weakness 0.00%
Stochastic Reached Oversold Weakness 0.00%
Down 3 Days in a Row Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
New 52 Week Closing Low Bearish -2.60%
Lower Bollinger Band Touch Weakness -2.60%
NR7 Range Contraction -4.53%

Older signals for OCUL ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Ocular Therapeutix, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of therapies based on its proprietary hydrogel platform technology for treating eye diseases and conditions. The company offers ReSure Sealant, a topical liquid hydrogel that creates a sealant to prevent post-surgical leakage from clear corneal incisions made during cataract surgery Its lead product candidates comprise OTX-DP, which is in Phase III clinical trials for the treatment of post-surgical ocular inflammation and pain; and OTX-TP that is in Phase II clinical trials for the treatment of glaucoma and ocular hypertension. The company's earlier stage product candidates include OTX-DP, which is in Phase II clinical trials for the treatment of allergic conjunctivitis; OTX-MP that has completed Phase I clinical trials for the treatment of bacterial conjunctivitis; and Anti-VEGF hydrogel depot, which is in preclinical testing for the treatment of wet AMD. Ocular Therapeutix, Inc. sells its ReSure Sealant through a network of independent medical device distributors in the United States. The company was founded in 2006 and is headquartered in Bedford, Massachusetts.
Health Medical Specialties Pain Clinical Trial Glaucoma Cataract Treatment Of Glaucoma Eye Diseases Incisions Allergic Conjunctivitis Allergology Cataract Surgery Ocular Hypertension Post Surgical Ocular Inflammation
Is OCUL a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 8.28
52 Week Low 3.31
Average Volume 487,225
200-Day Moving Average 4.9347
50-Day Moving Average 3.9128
20-Day Moving Average 3.729
10-Day Moving Average 3.596
Average True Range 0.2102
ADX 18.6
+DI 13.9285
-DI 27.5343
Chandelier Exit (Long, 3 ATRs ) 3.5194
Chandelier Exit (Short, 3 ATRs ) 3.9406
Upper Bollinger Band 4.1113
Lower Bollinger Band 3.3467
Percent B (%b) 0.03
BandWidth 20.504157
MACD Line -0.1273
MACD Signal Line -0.1004
MACD Histogram -0.0268
Fundamentals Value
Market Cap 97.92 Million
Num Shares 29.1 Million
EPS -2.15
Price-to-Earnings (P/E) Ratio -1.57
Price-to-Sales 88.04
Price-to-Book 3.48
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.69
Resistance 3 (R3) 3.70 3.61 3.63
Resistance 2 (R2) 3.61 3.53 3.60 3.61
Resistance 1 (R1) 3.49 3.48 3.45 3.48 3.60
Pivot Point 3.40 3.40 3.38 3.39 3.40
Support 1 (S1) 3.28 3.32 3.24 3.27 3.14
Support 2 (S2) 3.19 3.27 3.18 3.13
Support 3 (S3) 3.07 3.19 3.11
Support 4 (S4) 3.06